Clinical Trial Update: The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

View source ↗

Summary

This document reports on a randomized study evaluating dasatinib in combination with high-dose imatinib (600 mg) for suboptimal responders with chronic myeloid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (imatinib) (imatinib)
• Sprycel (dasatinib) (dasatinib)

Snippet

Sponsor: Pusan National University Hospital | Conditions: Chronic Myeloid Leukemia | Status: AVAILABLE